Twist's SARS-CoV-2 quality controls added to FDA materials Twist Bioscience's synthetic SARS-CoV-2 RNA quality controls for the development, verification, and validation of diagnostic tests for SARS-CoV-2 are now included in the U.S. Food and Drug Administration's (FDA) reference materials.
Frontera supercomputer aids COVID-19 drug development Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million atoms. This work was conducted as a collaboration between the Amaro Lab of the University of California, San Diego and the National Science Foundation-funded Frontera supercomputer at the University of Texas at Austin.
Dynavax, Clover partner for protein-based COVID-19 vaccine A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership, announced on March 24, will advance Clover's vaccine candidate, COVID-19 S-Trimer, with Dynavax providing its technical expertise and CpG 1018, a proprietary toll-like receptor 9 agonist adjuvant.